Lido Advisors
GSK icon

Lido Advisors’s GSK GSK Stock Holding History

Lido Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Buy
53,879
+319
+0.6% +$16.9K 0.01% 681
2026
Q1 		$2.96M Buy
53,560
+7,889
+17% +$427K 0.01% 590
2025
Q4 		$2.21M Buy
45,671
+34,125
+296% +$1.59M 0.01% 689
2025
Q3 		$503K Sell
11,546
-3,192
-22% -$125K ﹤0.01% 1230
2025
Q2 		$572K Buy
14,738
+670
+5% +$25.6K ﹤0.01% 1063
2025
Q1 		$550K Sell
14,068
-8,885
-39% -$325K ﹤0.01% 991
2024
Q4 		$785K Buy
22,953
+1,265
+6% +$45.5K ﹤0.01% 851
2024
Q3 		$887K Sell
21,688
-1,580
-7% -$64.6K ﹤0.01% 757
2024
Q2 		$902K Buy
23,268
+7,677
+49% +$323K 0.01% 698
2024
Q1 		$672K Buy
15,591
+6,795
+77% +$280K ﹤0.01% 791
2023
Q4 		$329K Buy
8,796
+1,440
+20% +$51.7K ﹤0.01% 996
2023
Q3 		$267K Sell
7,356
-334
-4% -$11.9K ﹤0.01% 966
2023
Q2 		$274K Buy
7,690
+156
+2% +$5.6K ﹤0.01% 972
2023
Q1 		$268K Buy
7,534
+92
+1% +$3.22K ﹤0.01% 904
2022
Q4 		$262K Sell
7,442
-4,120
-36% -$137K ﹤0.01% 832
2022
Q3 		$339K Buy
11,562
+2,144
+23% +$81.3K ﹤0.01% 700
2022
Q2 		$512K Sell
9,418
-196
-2% -$10.8K 0.01% 534
2022
Q1 		$523K Sell
9,614
-421
-4% -$22.9K 0.01% 589
2021
Q4 		$553K Sell
10,035
-1,323
-12% -$68.8K 0.01% 576
2021
Q3 		$542K Sell
11,358
-133
-1% -$6.68K 0.01% 564
2021
Q2 		$579K Buy
11,491
+309
+3% +$14.8K 0.01% 506
2021
Q1 		$499K Buy
11,182
+156
+1% +$7.08K 0.01% 500
2020
Q4 		$514K Buy
11,026
+4,778
+76% +$219K 0.01% 472
2020
Q3 		$298K Buy
6,248
+634
+11% +$31.8K 0.01% 492
2020
Q2 		$290K Buy
5,614
+220
+4% +$11.3K 0.01% 454
2020
Q1 		$259K Sell
5,394
-354
-6% -$18.9K 0.01% 449
2019
Q4 		$342K Buy
5,748
+1,556
+37% +$86.6K 0.01% 464
2019
Q3 		$226K Buy
+4,192
New +$216K 0.01% 525

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lido Advisors's GSK Position: Q2 2026 in Review

Lido Advisors increased its GSK (GSK) stake by 0.6% in Q2 2026, buying an estimated $16.9K and bringing the position to 53,879 shares worth $2.83M. The position accounts for 0.01% of the portfolio, ranked #681.

Lido Advisors first reported a position in GSK in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.96M in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Lido Advisors held 53,879 shares of GSK worth $2.83M as of Q2 2026.
  • Lido Advisors bought 319 GSK shares in Q2 2026, an estimated $16.9K.
  • GSK made up 0.01% of Lido Advisors's portfolio in Q2 2026, its #681 holding.
  • Lido Advisors first reported a position in GSK in Q3 2019 and has held it in 28 quarters since.
  • Lido Advisors's GSK position peaked at $2.96M in Q1 2026.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.